MOTS-c
Also known as: Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide, MOTSc, MOTS-C
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mtDNA 12S rRNA region, studied as an "exercise mimetic" that activates AMPK to improve insulin sensitivity, glucose handling, and exercise capacity in mice. It is explicitly prohibited by WADA at all times under S4.4.1 (AMPK activators), but that anti-doping listing reflects a category-wide policy line against metabolic modulators, not evidence that it pushes the human muscular/physique ceiling beyond natural. The exogenous-peptide evidence is almost entirely from mice, human data on injecting MOTS-c is essentially absent, and functionally it behaves like an AMPK-pathway metabolic-support agent (in the same family as metformin) rather than a proven muscle-, strength-, or fat-loss driver. Because it does not build muscle, does not raise anabolic hormones, and has no verified body-composition effect in humans, it is rated 1, basically natty, with no established effect on the muscular/physique/performance scale.
Overview
A 16-amino-acid peptide encoded not in the nuclear genome but within the mitochondrial 12S rRNA region, one of the first-described "mitochondrial-derived peptides." MOTS-c behaves as an exercise mimetic: it activates the AMPK energy-sensing pathway, improves insulin sensitivity and glucose disposal, promotes fat oxidation, and in animals restores age-related declines in physical capacity. It is studied for metabolic health, longevity, and endurance rather than muscle growth.
Purpose & Use Cases
Insulin Sensitivity & Glucose Control
Activates AMPK to enhance glucose uptake and disposal, the core, best-supported effect in animal models of aging and obesity.
Exercise-Mimetic / Endurance
In mice, MOTS-c increased running capacity and offset age-related physical decline, mimicking some adaptations of training.
Metabolic Health & Fat Oxidation
Promotes beta-oxidation and reduces fat accumulation, of interest for metabolic/recomposition goals.
Longevity
As a mitochondrial-derived peptide tied to AMPK and metabolic homeostasis, it is used in the longevity/biohacking context alongside other cellular-health agents.
Benefits
- Improves insulin sensitivity and glucose disposal (strong animal data)
- Activates AMPK, mimicking aspects of exercise and fasting
- Promotes fat oxidation without changing food intake in animal studies
- Restored age-related physical/exercise decline in mice
- Does not suppress testosterone, no PCT required
- Non-hormonal metabolic/longevity angle
Good to Know
Encoded by your mitochondria, not your nucleus
MOTS-c is one of a small family of "mitochondrial-derived peptides" written into the mtDNA 12S rRNA region. That novelty is much of its scientific appeal. It is a signalling molecule the mitochondria themselves produce to influence whole-body metabolism.
Banned in sport as an AMPK activator, not as an anabolic
MOTS-c is explicitly prohibited at all times under WADA S4.4.1 (activators of AMPK), the same metabolic-modulator subsection as agents like AICAR. It is banned because it mimics exercise, not because it builds muscle, and no TUE is available since there is no approved therapeutic use.
Almost all evidence is preclinical
The impressive insulin-sensitivity, fat-loss, and endurance results (Lee/Kim 2015-2019, Reynolds 2021) are from mice and cell studies. Human trials measure endogenous MOTS-c as an exercise/health biomarker; controlled trials of injecting exogenous MOTS-c in people are essentially absent. Physique/longevity use is extrapolation.
Not a muscle-builder and not hormonal
MOTS-c does not raise testosterone, aromatize, or interact with DHT/hair loss, no AI or PCT considerations apply. Its lane is metabolic health, glucose control, and endurance, not size or strength.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 5 – 10 mg/week |
| Intermediate | 10 – 15 mg/week |
| Advanced | 15 – 30 mg/week |
There is no validated human dose or published human trial of injected MOTS-c. Every figure here is extrapolated from community/biohacker protocols, which vary across sources (roughly 5mg/week on conservative protocols up to ~25-30mg/week on more assertive community protocols, e.g. 5mg dosed 5x/week), so treat this range as community-derived and unvalidated rather than clinical. For reference, the pivotal mouse studies used intraperitoneal doses of 0.5-5mg/kg/day (Lee et al. 2015) and 5-15mg/kg/day (Reynolds et al. 2021); naive human-equivalent scaling of those doses lands well above what most community protocols actually use. MOTS-c is usually run in cycles (commonly 4-12 weeks) rather than continuously. Reconstitute with bacteriostatic water and keep refrigerated. Because it improves glucose uptake, anyone using insulin or other glucose-lowering drugs should watch for additive hypoglycemia.
Plasma half-life is short (minutes to a few hours), but the AMPK-signalling effects outlast the measurable peptide.
Side Effects
Injection Site Reaction
commonRedness or irritation at the subcutaneous injection site.
Rotate injection sites; sterile technique.
Hypoglycemia-type Symptoms
uncommonBecause it improves glucose uptake, some users report light-headedness or shakiness, especially fasted or when combined with other glucose-lowering agents.
Do not dose fasted if prone to it; be cautious combining with insulin/GLP-1s; keep fast carbs available.
Fatigue / Flu-like Feeling
uncommonOccasional reports of transient fatigue or malaise after dosing.
Lower dose; usually transient.
Sourcing / Purity Risk
commonUnregulated research peptide: actual content and purity vary by supplier.
Use a tested product with a certificate of analysis.
General Mitigation Strategies
MOTS-c is reported as generally well tolerated in community use, with injection-site reactions the most common complaint. The main physiological caution is additive blood-glucose lowering when stacked with insulin, GLP-1 agonists, or metformin. As always with research peptides, product quality is the biggest practical risk.
Post Cycle Therapy (PCT)
Not hormonal. Does not affect the HPTA or testosterone. No PCT required.
How It Works
Under metabolic stress, MOTS-c translocates from the mitochondria to the nucleus and helps regulate the cellular stress and metabolic response. Functionally it activates AMP-activated protein kinase (AMPK) (the same low-energy sensor that exercise, metformin, and fasting engage) which promotes glucose uptake, increases fatty-acid beta-oxidation, and shifts cells toward using fuel efficiently rather than storing it. In aged and diet-induced-obese mice, MOTS-c improved whole-body insulin sensitivity (roughly a 30% rise in glucose infusion rate in clamp studies), reduced fat accumulation, and increased running capacity, which is why it is described as an exercise mimetic.
Fundamentals
Reference on the practices relevant to MOTS-c: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- MOTS-c + Metformin - Metabolic/longevity AMPK-focused pairing
- MOTS-c + Cardarine/Stenabolic - Exercise-mimetic endurance and fat-oxidation stack
- MOTS-c + NAD+ - Mitochondrial/cellular-energy longevity combo
Legal Status
Research chemical (USA). WADA prohibited at all times (S4.4.1 AMPK activators). Not FDA-approved for human use.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
MOTS-c is named/captured under S4.4.1 as an AMPK activator and is prohibited at all times. USADA states no TUE is available because it has no approved therapeutic use.
References
- Lee et al. 2015: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metab, PMC4350682)
- Kim et al. 2018: MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (Cell Metab, PMC6185997)
- Kim et al. 2019: MOTS-c regulates plasma metabolites and enhances insulin sensitivity (Physiol Rep, PMC6640593)
- Reynolds et al. 2021: MOTS-c is an exercise-induced regulator of age-dependent physical decline (Nat Commun)
- USADA, What is the MOTS-c peptide? (WADA S4.4.1 status)